[G26-06] Imipenem/Cilastatin/Relebactam (bacterial infections, several therapeutic indications, < 18 years) – Assessment according to §35a (para. 1c)

In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

After completion of the assessment by IQWiG, the G-BA conducts a commenting procedure. Following the hearing, the G-BA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.